Top Markets
#1 Black Phoenix Black Phoenix +199.74%
#2 Islamic Coin Islamic Coin +158.05%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +56.25%
#5 Akedo Akedo +41.31%
#6 BasedHype BasedHype +32.44%
#7 Acurast Acurast +26.87%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.07%
#9 Cryptopia Cryptopia +22.04%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +17.37%
Coin of the day
Black Phoenix Black Phoenix
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Xếp hạng trong cổ phiếu #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Giá cổ phiếu
$0.0005
Đồng bộ lần cuối: 2026-08-11
Vốn hóa thị trường
$10.28K
Thay đổi (1 ngày)
0.00%
Thay đổi (1 năm)
0.00%
Quốc gia
US
Giao dịch VIA Pharmaceuticals, Inc. (VIAP)

Danh mục

Healthcare
Lịch sử lợi suất cổ tức của VIA Pharmaceuticals, Inc. (VIAP)
Lợi suất cổ tức (TTM) của VIA Pharmaceuticals, Inc. (mã cổ phiếu: VIAP) tại thời điểm 2026 là: 0
Lợi suất cổ tức trung bình trong 5 năm qua: 0.00%
Lịch sử lợi suất cổ tức của VIA Pharmaceuticals, Inc. (VIAP) từ 2026 đến 2026
Lợi suất cổ tức vào cuối mỗi năm (TTM)
Năm Lợi suất cổ tức Thay đổi
Không đủ dữ liệu cho ngày được cung cấp.
Lợi suất cổ tức (TTM) của các công ty tương tự hoặc đối thủ
Công ty Lợi suất cổ tức Quốc gia
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
1.56%
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
0.00%
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
0.00%
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
0.00%
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
0.00%
US